JIP
NVO

Jaffetilchin Investment Partners’s Novo Nordisk NVO Stock Holding History

Jaffetilchin Investment Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,924
Closed -$409K – 457
2025
Q2 		$409K Buy
+5,924
New +$403K 0.03% 284
2024
Q4 		– Sell
-594
Closed -$70.7K – 969
2024
Q3 		$70.7K Buy
+594
New +$79.2K 0.01% 513
2016
Q1 		– Sell
-12,798
Closed -$372K – 228
2015
Q4 		$372K Buy
12,798
+788
+7% +$21.8K 0.12% 116
2015
Q3 		$326K Sell
12,010
-4,978
-29% -$141K 0.12% 130
2015
Q2 		$465K Buy
+16,988
New +$478K 0.14% 127
2014
Q3 		– Sell
-17,010
Closed -$393K – 232
2014
Q2 		$393K Buy
+17,010
New +$376K 0.14% 111
2014
Q1 		– Sell
-17,400
Closed -$321K – 213
2013
Q4 		$321K Buy
17,400
+1,480
+9% +$25.8K 0.16% 130
2013
Q3 		$269K Sell
15,920
-22,100
-58% -$372K 0.16% 145
2013
Q2 		$589K Buy
+38,020
New +$633K 0.41% 65

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jaffetilchin Investment Partners's NVO Position: Q3 2025 in Review

Jaffetilchin Investment Partners sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 5,924 shares — an estimated $409K sold.

Jaffetilchin Investment Partners first reported a position in NVO in Q2 2013 and held it in 9 quarters. The position peaked at $589K in Q2 2013. 1,396 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Jaffetilchin Investment Partners reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 5,924 Novo Nordisk shares in Q3 2025, an estimated $409K.
  • Jaffetilchin Investment Partners first reported a position in Novo Nordisk in Q2 2013 and held it in 9 quarters.
  • Jaffetilchin Investment Partners's Novo Nordisk position peaked at $589K in Q2 2013.
  • 1,396 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Jaffetilchin Investment Partners's 13F filing for Q3 2025, filed 13 Nov 2025.